AstraZeneca digs deeper into cancer with Innate stake
AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | France Health | Health | Immunotherapy | Pharmaceuticals | UK Health